Ronald Blaylock - Pfizer Independent Director

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:3em;padding-top: 38px;;'>PFE</div>
PFE -- USA Stock  

Trending

  Director
Mr. Ronald E. Blaylock is an Independent Director of Pfizer Inc. He is Founder, Managing Partner of GenNx360 Capital Partners, a private equity firm focused on investing in industrial and business services companies in the U.S. middle market, since 2006. Prior to launching GenNx360 Capital Partners, Mr. Blaylock founded and managed Blaylock Company, an investment banking firm. Also held senior management positions at UBS, PaineWebber Group and Citicorp. Director of CarMax, Inc., Radio One, Inc. and W.R. Berkley, Inc., an insurance holding company. Director of Syncreon U.S., a forprofit private company. Member of the Board of Trustees of Carnegie Hall. Member of the Board of Overseers of New York University Stern School of Business. Member of the Board of Trustees of Prep for Prep, a notforprofit organization.
Age: 59  Director Since 2017      
212 733-2323  www.pfizer.com

Ronald Blaylock Latest Insider Activity

Pfizer Management Efficiency

Pfizer Inc has Return on Asset of 5.78 % which means that on every $100 spent on asset it made $5.78 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 25.41 %, implying that it generated $25.41 on every 100 dollars invested. Pfizer management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. The current year Return on Investment is expected to grow to 11.02, whereas Return on Average Assets are expected to decline to 8.28. Pfizer Current Assets are expected to decrease significantly based on the last few years of reporting. The past year's Current Assets were at 32.8 Billion. The current year Tax Assets is expected to grow to about 6.1 B, whereas Goodwill and Intangible Assets are expected to decline to about 89.2 B. Pfizer Tax Liabilities is expected to decrease significantly based on the last few years of reporting. The past year's Tax Liabilities was at 18.68 Billion
The company has 52.29 B in debt with debt to equity (D/E) ratio of 0.8, which is OK given its current industry classification. Pfizer Inc has a current ratio of 1.0, demonstrating that it may have difficulties to pay its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Geoffrey ParkerPerrigo Company Plc
2016
George SingRegeneron Pharmaceuticals
1988
Sanjay KhoslaZoetis Inc
2013
Gary KunklePerrigo Company Plc
2009
Anupam PuriDr Reddys Laboratories
2002
J MoreauDr Reddys Laboratories
2007
Omkar GoswamiDr Reddys Laboratories
2000
Bonnie BasslerRegeneron Pharmaceuticals
2016
Bruce SachsVertex Pharmaceuticals Incorpor
2017
Jeffrey KindlerPerrigo Company Plc
2017
Hans HaslerDr Reddys Laboratories
2016
Christine PoonRegeneron Pharmaceuticals
2010
Gary CohenPerrigo Company Plc
2009
Michael GallagherAllergan Plc
2015
Marc TessierLavigneRegeneron Pharmaceuticals
2011
Christopher CoughlinAllergan Plc
2016
Ravi BhoothalingamDr Reddys Laboratories
2000
Jeffrey SmithPerrigo Company Plc
2017
David AltshulerVertex Pharmaceuticals Incorpor
2015
Louise ParentZoetis Inc
2013
Robert ScullyZoetis Inc
2013

Company Summary

Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer operates under Drug ManufacturersGeneral classification in the United States and is traded on BATS Exchange. It employs 88300 people.Pfizer Inc (PFE) is traded on BATS Exchange in USA and employs 88,300 people.

Pfizer Inc Leadership Team

John Young, Group President - Pfizer Innovative Health and Angela Hwang
Jennifer Damico, Senior Vice President Principal Accounting Officer, Controller
Frank DAmelio, Chief Financial Officer, Executive Vice President - Business Operations and Global Supply
Douglas Lankler, Executive Vice President General Counsel
Dawn Rogers, Chief Human Resource Officer, Executive Vice President
Helen Hobbs, Independent Director
Shantanu Narayen, Lead Independent Director
James Smith, Independent Director
Dennis Ausiello, Independent Director
Mikael Dolsten, Chief Scientific Officer, President - Worldwide Research, Development and Medical
Susan DesmondHellmann, Director
Frances Fergusson, Independent Director
Stephen Sanger, Independent Director
Lidia Fonseca, Executive Vice President, Chief Technology Officer and Digital Officer
Gordon Loh, Senior Vice President Corporate Audit
Wyllie Cornwell, Independent Director
Suzanne Johnson, Independent Director
Alexander Mackenzie, Executive Vice President Chief Development Officer
Geno Germano, Group President of Global Innovative Pharma Bus.
Laurie Olson, Executive Vice President - Strategy, Portfolio and Commercial Operations
Sally Susman, Chief Corporate Affairs Officer, Executive Vice President
Anthony Maddaluna, Executive Vice President and Presidentident - Pfizer Global Supply
Susan Hockfield, Independent Director
Freda LewisHall, Executive Vice President Chief Medical Officer
Rady Johnson, Chief Compliance, Quality and Risk Officer, Executive Vice President
Dan Littman, Independent Director
Ian Read, Chairman, CEO and Chairman of Executive Committee
James Kilts, Independent Director
Don Cornwell, Independent Director
James Quincey, Independent Director
Charles Hill, Executive Vice President - Worldwide Human Resources
Joseph Echevarria, Independent Director
Albert Bourla, Group President - Vaccines, Oncology and Consumer Healthcare Business
Kirsten LundJurgensen, Executive Vice President and Presidentident - Pfizer Global Supply
Angela Hwang, Group President, Pfizer Biopharmaceuticals Group
Scott Gottlieb, Independent Director
Ronald Blaylock, Independent Director
Kathrin Jansen, Senior Vice President - Vaccine Research & Development
Michael Goettler, Group President - Pfizer Upjohn

Stock Performance Indicators

Did you try this?

Run Price Transformation Now

   

Price Transformation

Use Price Transformation models to analyze depth of different equity instruments across global markets
All  Next Launch Module

Currently Active Assets on Macroaxis

S   
Sold over 300 shares of
six days ago
Traded for 8.62
GM   
Sold over 100 shares of
six days ago
Traded for 25.24
XOM   
Sold over 60 shares of
six days ago
Traded for 44.08
OTPBF   
Sold over 100 shares of
six days ago
Traded for 28.82
MSFT   
Sold few shares of
six days ago
Traded for 206.26
Please check Your Equity Center. Please also try Commodity Channel Index module to use commodity channel index to analyze current equity momentum.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page